tiprankstipranks
Advertisement
Advertisement

MXCT Stock Latest News

MaxCyte Shareholders Reelect Directors and Ratify Auditor
Company AnnouncementsMaxCyte Shareholders Reelect Directors and Ratify Auditor
14d ago
8K
MXCT
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
PremiumCompany Announcements
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
15d ago
8K
MXCT
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
PremiumCompany Announcements
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
2M ago
MXCT
MaxCyte reports Q1 EPS (4c), consensus (9c)
PremiumThe Fly
MaxCyte reports Q1 EPS (4c), consensus (9c)
2M ago
MXCT
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
PremiumThe Fly
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
2M ago
MXCT
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
PremiumCompany AnnouncementsMaxCyte Reports Q1 2026 Results, Launches Share Buyback
2M ago
8K
MXCT
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
Premium
Ratings
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
3M ago
MXCT
MaxCyte Appoints New Chief Financial Officer Ahuja
Premium
Company Announcements
MaxCyte Appoints New Chief Financial Officer Ahuja
3M ago
8K
MXCT
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
PremiumCompany Announcements
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
3M ago
MXCT
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
PremiumCompany Announcements
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
3M ago
MXCT
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
PremiumThe Fly
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
3M ago
MXCT
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
PremiumCompany Announcements
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
3M ago
8K
MXCT
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
PremiumThe FlyMaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
3M ago
MXCT
MaxCyte reports Q4 EPS (9c), consensus (8c)
Premium
The Fly
MaxCyte reports Q4 EPS (9c), consensus (8c)
3M ago
MXCT
MaxCyte appoints Parmeet Ahuja as CFO
Premium
The Fly
MaxCyte appoints Parmeet Ahuja as CFO
3M ago
A
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
PremiumCompany Announcements
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
3M ago
8K
MXCT
MaxCyte announced the launch of ExPERT DTx
PremiumThe Fly
MaxCyte announced the launch of ExPERT DTx
4M ago
MXCT
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
PremiumThe Fly
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
6M ago
MXCT
MaxCyte management to meet with Craig-Hallum
PremiumThe Fly
MaxCyte management to meet with Craig-Hallum
7M ago
MXCT
MaxCyte CFO Douglas Swirsky to transition out of role
PremiumThe FlyMaxCyte CFO Douglas Swirsky to transition out of role
8M ago
MXCT
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
Premium
The Fly
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
8M ago
MXCT
MaxCyte reports Q3 EPS (12c), consensus (9c)
Premium
The Fly
MaxCyte reports Q3 EPS (12c), consensus (9c)
8M ago
MXCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >